Alterity Therapeutics Limited

Healthcare · Biotechnology · Australia

Last price 2.2335 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 41.92M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as we...